Black participants severely underrepresented in global oncology studies

The importance of diversity in clinical trials has increasingly become a key issue within the pharmaceutical industry. If trial participants are representative of the wider disease population, clinical trials can effectively assess the safety and effectiveness of new or existing therapeutics. A lack of diversity in clinical trial populations significantly diminishes the quality of data obtained for drug safety and efficacy profiles. This lack of diversity is a significant issue facing the oncology field. GlobalData has found that Black participants are severely underrepresented in oncology studies, with a 3% involvement in global clinical trials from 2013 to the present.